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In the previous issue of Critical Care Mecott and colleagues 
report the eﬀ  ects of a glucagon-like peptide-1 (GLP-1) 
analogue, exenatide, on glycaemia in severely burned 
paediatric patients [1]. Th  e incretin hormones, GLP-1 
and glucose-dependent polypeptide (GIP), mediate ~70% 
of the insulin response to a meal [2]. While GIP is 
potently insulinotropic in health, its eﬀ  ect is markedly 
attenuated in type 2 diabetic patients, such that even 
pharmacological doses have little eﬀ  ect on glycaemia [3]. 
In contrast, physiological replacement or pharmaco-
logical adminis  tra  tion of GLP-1 lowers glycaemia sub-
stantially in this group [3]. Accordingly, studies in 
ambulant type 2 diabetic patients have focused on the 
therapeutic potential administration of GLP-1 rather 
than GIP. Signiﬁ     cantly, the glucose-lowering eﬀ  ects of 
exogenous GLP-1 are glucose dependent, such that even 
pharma  co  logical doses of GLP-1 are most unlikely to 
cause hypo  glycaemia.
Native GLP-1 is not used as a glucose-lowering agent in 
ambulant type 2 diabetic patients because of the necessity 
for continuous administration [4]. Endogenous GLP-1 is 
metabolised rapidly to its so-called inactive metabolite by 
the ubiquitous enzyme dipeptyl-peptidase-4 (DPP-4), the 
half-life of native GLP-1 being ~1 to 2 minutes [5]. While 
this factor essentially precludes the use of exogenous 
GLP-1 in ambulant patients, rapid metabolism of an 
agent may be a desirable pharmacokinetic property in the 
hospitalised patient. Accordingly, our group and others 
have explored the eﬀ  ects of exogenous GLP-1 in a variety 
of hospitalised, adult patients [6-10].
Usin    g a prospective, randomised, open-label, design, 
Mecott and colleagues compared an intervention 
(exenatide ± insulin) with a control (intensive insulin 
therapy) i    n patients receiving small intestinal nutrient. 
Th  e authors report that the intervention decreased 
insulin requirements while comparable glycaemic control 
was achieved. Th   e therapeutic use of GLP-1 in critically 
ill patients is inherently attractive as it does not 
substantially increase the risk of hypoglycaemia [11]. In 
addition, GLP-1 therapies show reduced glycaemic varia-
bility when compared with insulin in ambulant diabetic 
patients [11].
Strengths of the study are the evaluation of a GLP-1-
based therapy in a new population (paediatric) that has 
suﬀ  ered  a  speciﬁ   c insult (burns), and the prolonged 
duration of evaluation (up to 28 days). Finally, and per-
haps most signiﬁ  cantly, the investigators have elected to 
use a GLP-1 analogue (exenatide) rather than the syn-
thetic peptide. Th   e major advantages of exenatide when 
compared with GLP-1 are that it can be administered 
intermittently, as well as its cheaper price and ready 
availability (Table 1).
Limitations of the study, which are largely acknow-
ledged by the authors, include its open-label design and 
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consequent potential for type 2 errors. Th  e authors 
reported that the use of the GLP-1 analogue failed to 
reduce hypoglycaemic episodes and glycaemic variability. 
However, the lack of eﬀ   ect on variability and hypo-
glycaemia may reﬂ   ect administration of exenatide ± 
insulin, rather than using exenatide as a single agent. 
Plasma exenatide concentrations were not reported, and 
it should be recognised that concentrations may not be 
predictable in these subjects – since, even in healthy 
subjects, exenatide has a biological half-life of ~3 hours 
and large ﬂ  uctuations in plasma levels occur with twice-
daily subcutaneous administration. Furthermore, given 
the limited infor  mation on the mechanisms of glucose-
lowering in the critically ill patient, measurement of 
insulin and/or C-peptide, as well as glucagon, would have 
been valuable.
Exendin-4 was isolated originally from the saliva of the 
Gila monster (Heloderma suspectum), a slow-moving 
venomous lizard native to the United States and Mexico. 
Th   e Gila monster eats only 5 to 10 times per year and a 
meal causes a substantial postprandial increase in plasma 
exendin-4 concentrations [12]. Exendin-4 shares ~50% 
amino acid sequence identity with human GLP-1 and 
binds to the pancreatic GLP-1 receptor in vitro. Impor-
tantly, exendin-4 is resistant to DPP-4 inactivation, 
thereby having a prolonged duration of action [12]. 
Exenatide, a synthetic form of exendin-4, has been shown 
to reduce fasting and postprandial glucose via glucose-
dependent stimulation of insulin and suppression of 
glucagon secretion, as well as slowing gastric emptying 
[13]. Th   e latter is probably the dominant mechanism to 
account for glucose lowering after oral or intragastric 
meals in healthy subjects, type 2 diabetic patients, and 
those critically ill patients in whom gastric emptying is 
normal [10,13]. GLP-1 analogues with half-lives between 
12 hours and 3 to 4 days have been recently developed. 
Th  ese analogues have less variation in plasma concen-
trations after once-daily (for example, liraglutide) or 
weekly (sustained release exenatide) administration than 
twice a day dosing (exenatide). Oral drugs that inactivate 
the DPP-4 enzyme (DPP-4 inhibitors) – thereby 
attenuating metabolism and increasing the availability of 
endogenous GLP-1 and GIP – have also entered the 
clinical domain (Table 1).
In the study of Mecott and colleagues, exenetide was 
well tolerated; but given the adverse eﬀ  ects associated 
with its use in ambulant diabetic patients, ongoing 
vigilance is warranted. Th  ese adverse eﬀ  ects  include 
nausea and vomiting (usually transient) [14], as well as 
modest weight loss that occurs, and is frequently 
desirable, in ambulant type 2 diabetic patients [14], but 
may be detrimental in the critically ill patient. Th  e 
potential association between GLP-1 analogues and 
pancreatitis remains uncertain [14]. Lastly, the investi-
gators did not measure anti-exenatide antibodies or 
plasma calcitonin concentrations, but the signiﬁ  cance of 
anti-exenatide antibiodies or mild increases in calcitonin 
concentrations is unclear [14].
Albeit preliminary, the present study represents part of 
a growing interest in the use of incretins, or incretin 
mimetics, for the management of hyperglycaemia in 
hospitalised patients [15]. Th  e desirable blood glucose 
range in this group remains contentious, but, as with 
recent studies in ambulant type 2 diabetic patients, there 
seems to be minimal, or no, advantage in targeting 
glycaemia at the lower end of the fasting normal range. 
Rather, the latter may well be deleterious [16]. Because 
the glucose-lowering eﬀ   ect of GLP-1 is glucose 
dependent, there is likely to be a threshold – perhaps 
Table 1. Comparison between GLP-1, GLP-1 analogues and DPP-4 inhibitors
  GLP-1  GLP-1 analogues  DPP-4 inhibitors
Name(s) GLP-1-(7-36)NH2  Exena  tide  Sitagliptin
    Lir  aglutide  Vildagliptin
    Saxagliptin
Administration Intravenous  Subcutaneous  Oral
Studied in the critically ill patient  Yes  Yes  No
Current cost  Prohibitive  Expensive  Expensive
Availabil  ity  Limited  Yes  Yes
Half      -life  1 to 2 minutes  2 to 15 hours  2 to 14 hours
Additional eff  ects mediated via inactive GLP-1  Yes  No  No
Nausea  Yes Yes No
Weight    Loss Loss Weight  neutral
Gastric emptying  Slows  Slows  Minimal, if any, eff  ect
DPP-4, dipeptyl-peptidase-4; GLP-1, glucagon-like peptide-1.
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will only occur if exogenous insulin is co-administered. 
In addition to identifying the optimal glycaemic range, 
future studies should focus on the following: which of the 
incretin agents is most useful in the critically ill patient; 
whether these agents should be used in combination with 
insulin, or as single-agent therapy; and identiﬁ  cation of 
the patient group most likely to beneﬁ  t  from 
administration of incretin mimetics.
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